Cardiovascular benefits and safety of sotagliflozin in type 2 diabetes mellitus patients with heart failure or cardiovascular risk factors: a bayesian network meta-analysis

• Main Authors: Jiyifan Li (Author), Chenyang Zhu (Author), Jingru Liang (Author), Jiarong Hu (Author), Haiyang Liu (Author), Zihan Wang (Author), Ruifang Guan (Author), Junwei Chow (Author), Shiwei Yan (Author), Longzhou Li (Author), Fuyan Ma (Author), Guo Ma (Author)
• Format: Book
• Published: Frontiers Media S.A., 2023-11-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Background: As an antidiabetic agent, sotagliflozin was recently approved for heart failure (HF). However, its cardiovascular benefits in type 2 diabetic mellitus (T2DM) patients with HF or cardiovascular (CV) risk factors have not been systematically evaluated. The aim of this study is to evaluate...